David A. Gonyer - 08 Feb 2023 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Reporting relationship: CEO, Director
Issuer ticker: EVOK
Reported as of: 08 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2023, 15:13:14 UTC
Prior SEC filing: 04 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Matthew J. D'Onofrio, Attorney-in-fact for David A. Gonyer

Key filing fact

David A. Gonyer filed Form 4 for Evoke Pharma Inc (EVOK) on 10 Feb 2023.

Key facts

This page summarizes David A. Gonyer's Form 4 filing for Evoke Pharma Inc (EVOK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Feb 2023, 15:13.

Change

Previous filing in this sequence was filed on 04 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVOK transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 08 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $4.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest at the rate of 1/48th of the original number of shares on each monthly anniversary of January 1, 2023, subject to the reporting person's continuous service to the issuer on each such vesting date.